392 trials
Obesity · Healthy Volunteers · Overweight
Primary: Correlation Between Striatal D2 Receptor Binding Potential (D2BP) as Measured by [18F]Fallypride and [11C]Raclopride Time-activity Curves — 0.468 Correlation Coefficient
Squamous Cell Carcinoma of the Oral Cavity
Primary: Area Under the Curve (AUC) for Matrine in Saliva — 4007.9 ng x h/mL
Elder Abuse
Primary: Implementation in Terms of Participation — 1012 Participants
Vitamin D and Calcium Homeostasis
Primary: 1, 25(OH) D3 Vitamin D — 3.2; 1.7; 3.7; -3.3 pM — p=0.884
Opioid Dependence
Primary: Study Enrollment — 7 Participants
Asthma
Primary: Change in Tolerance to Inhaled Methacholine — 5.3; 24.2 mg/ml
Cannabis Use Disorder · Cannabis Dependence, Continuous
Primary: Distribution Volume (VT) — 1.27; 1.54; 1.14; 1.31 mL/cm^3 — p=0.02
Cognitive Impairment, Mild · Alzheimer Disease
Primary: Blood Brain Barrier Penetration of RAPA — 0 ng/ml
Celiac Disease
Primary: Percentage of α1- and α2-gliadin-reactive CD4+ T Cells in Peripheral Blood Before Gluten Challenge — 0.00364; 0.00016; 0.00049; 0.00005 Percentage of T cells
Antibiotic-associated Diarrhea
Primary: Level of Fecal Short-chain Fatty Acid (SCFA) Acetate — 53.1; 45.2; 42.3; 38.1 micromolar (μM)
Chronic Pain · Opiate Dependence · Lower Back Pain
Primary: Change in Quantitative Pain Testing Following Active TMS Compared to Baseline — 1.4; .3 Change from Baseline (degrees C) — p=.83
Cocaine Use Disorder
Primary: Reinforcing Effects of Cocaine — 1.3; 5.0; 8.3; 0 Number of Cocaine Choices
Hyperglycaemia (Diabetic)
Primary: Change in HbA1c Levels — 24.3 mmol/mol — p=0.006
Idiopathic Pulmonary Fibrosis
Primary: EGCG PK Level in Healthy Volunteers — NA; NA; NA; 861 nM
Sedentary Lifestyle · Self-control
Primary: Objective Physical Activity — 6184.45; 6671.81; 6647.71; 6932.25 Average Daily Steps — p=0.038